Meeting Banner
Abstract #0310

Understanding the relationship between R2* and R1 MRI biomarkers of hypoxia: insights from 786-0 renal cancer xenografts and patients with renal carcinoma

Ross A Little1, Yann Jamin2, Jessica KR Boult2, Josephine H Naish1, Yvonne Watson1, Susan Cheung1, Huiqi Lu1, Damien J McHugh1, Geoff JM Parker1,3, Joely Irlam4, Catherine ML West4, John C Waterton1, Simon P Robinson2, and James PB O'Connor4,5

1Centre for Imaging Sciences, University of Manchester, Manchester, United Kingdom, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, London, United Kingdom, 3Bioxydyn Ltd, Manchester, United Kingdom, 4Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom, 5Department of Radiology, The Christie NHS Foundation Trust, Manchester, United Kingdom

Quantification of tumour R2* and oxygen-induced ΔR2* and ΔR1 are being investigated as potential biomarkers of tumour hypoxia, but their relationship is complex and not well understood. Here, we used a validated R1 biomarker (oxygen refractory fraction, termed “Oxy-R”) to segment tumours into hypoxic and non-hypoxic sub-regions. This revealed a clear relationship between hypoxic status and native R2* and hyperoxia-induced ΔR2*. Preclinical findings were replicated in clinical data from patients with renal carcinoma. These data highlight the importance of heterogeneity-based analysis of tumours and provide further validation of Oxy-R as a biomarker of tumour hypoxia.

This abstract and the presentation materials are available to members only; a login is required.

Join Here